Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
New genetic research is rewriting the fibromyalgia playbook. A landmark genome-wide study of over 2.5 million people found that fibromyalgia is rooted in the central nervous system — not autoimmunity or psychiatry. Experts say the findings should reshape how clinicians diagnose and treat the condition, with exercise, better sleep, and non-opioid medications leading the way.
Fibromyalgia has long been misunderstood — dismissed as autoimmune, psychiatric, or "all in the head." But two major papers published in Nature Medicine and the New England Journal of Medicine are making the case that it's fundamentally a central nervous system disorder, backed by the largest genetic study of the condition to date.
The Nature Medicine genome-wide association study analyzed data from over 2.5 million individuals and identified 26 genetic risk loci for fibromyalgia — all pointing to the CNS. Notably, the strongest association was with a coding variant in HTT, the gene implicated in Huntington's disease. The study also found genetic links to conditions like PTSD, IBS, low back pain, and other chronic pain disorders, with no differences in genetic architecture between sexes.
The companion NEJM clinical practice article, co-authored by Dr. Daniel Clauw of the University of Michigan, stresses that mislabeling fibromyalgia leads to mistreatment. Management should center on non-pharmacological approaches, with medications like duloxetine or cyclobenzaprine used judiciously.
Key Takeaways:
Why it matters: Misclassifying fibromyalgia as autoimmune or psychiatric delays effective care for millions of patients. These findings give clinicians a clearer, evidence-based framework for diagnosis and treatment — and a strong argument for better reimbursement of non-pharmacological therapies.
